Canaccord Genuity Maintains Buy on AtriCure, Raises Price Target to $55
Benzinga Newsdesk 5 months ago
NewsPrice TargetAnalyst Ratings
Canaccord Genuity analyst William Plovanic maintains AtriCure (NASDAQ:ATRC) with a Buy and raises the price target from $53 to $55.
Canaccord Genuity analyst William Plovanic maintains AtriCure (NASDAQ:ATRC) with a Buy and raises the price target from $53 to $55.